Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial.
David PowerUlrich SchäferRoxana MehranBimmer E ClaessenSamantha SartoriSabato SorrentinoThierry LefèvreChristian KupattDidier TchetcheNicolas DumonteilJohn G WebbAntonio ColomboStephen WindeckerJurriën M Ten BergDavid Hildick-SmithPeter BoekstegersAxel LinkeChristophe TronEric Van BelleAnita W AsgarRaban JegerGennaro SardellaUlrich HinkOliver HusserEberhard GrubeIlknur LechthalerPeter WijngaardProdromos AnthopoulosEfthymios N DeliargyrisDebra BernsteinChristian HengstenbergRoxana MehranGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
Compared to PS, the PG VCD was associated with a lower rate of major or minor vascular complications and lower rates of AKI after transfemoral TAVR.